Mitapivat Improves Markers of Erythropoietic Activity in Long-Term Study of Adults with Alpha- or Beta-Non-Transfusion-Dependent Thalassemia
Kevin H.M. Kuo(University Health Network), Elliott Vichinsky(Unknown), Penelope A. Kosinski(Agios Pharmaceuticals (United States)), Bo Tong(AbbVie (United States)), Hanny Al‐Samkari(Harvard University), Katrin Uhlig(Tufts Medical Center), Ashutosh Lal(Post Graduate Institute of Medical Education and Research), D. Mark Layton(Imperial College Healthcare NHS Trust), Jeremie H. Estepp(St. Jude Children's Research Hospital)
Cited by 6
Related Papers
Sickle cell disease
|Nature Reviews Disease Primers|2018|1.4k
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans
|Cell|2021|309
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Graft Use in Transvaginal Pelvic Organ Prolapse Repair
|Obstetrics and Gynecology|2008|163